Company intelligence / Profile preview

HemaCell

Suzhou, Jiangsu Province, China

Ownership: Private
Employees: ~10
Development stage: Other

Overview

HemaCell has developed an in vitro platelet production technology leveraging stem cell differentiation, targeting unmet clinical demand for platelets in hematologic, oncologic, and rare platelet disorders. No active clinical trials are listed on ClinicalTrials.gov as of July 2025[1][5].

Therapeutic areas: HematologyGastroenterology
Modalities: Induced pluripotent stem cell derived therapyStem cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on HemaCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HemaCell.

Explore the full profile